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Introduction: Twice-daily radiation with concurrent chemotherapy 
is recognized as the standard of care for the treatment of limited stage 
small-cell lung carcinoma (SCLC), but its utilization in this setting is 
unclear. The objective of this study was to analyze modern patterns 
of treatment for limited stage SCLC and the impact on survival uti-
lizing the National Cancer Database.
Methods: Between 1999 and 2012, there were 25,045 patients diag-
nosed with nonmetastatic SCLC who met the selection criteria, of 
whom 22,626 had survival data. Those receiving 45 Gy in 1.5 Gy 
fractions twice-daily (BID) were compared with those receiving 45 
to 72 Gy in 1.8 or 2.0 Gy fractions. Overall survival was analyzed 
via Kaplan–Meier analysis and compared using the log-rank test. 
Multivariate Cox regression analysis was used to identify covariates 
associated with survival.
Results: The utilization of BID radiation overall was 11.3%. 
Treatment at an academic center was associated with a higher likeli-
hood of receiving BID treatment (odds ratio: 2.29, 95% conﬁdence 
interval [CI]: 1.95–2.69; p < 0.001). Median survival was 22.1, 17.2, 
18.3, 19.2, and 19.5 months for patients receiving 45 Gy BID, 45 Gy 
once-daily, 46 to 59.4 Gy once-daily, 60 to 61.2 Gy once-daily, and 
62 to 72 Gy once-daily, respectively (p < 0.001 for all pairwise com-
parisons to BID). On multivariate analysis, treatment at an academic 
center (hazard ratio: 0.88, 95% CI: 0.83–0.93; p < 0.001) and receipt 
of BID radiation (hazard ratio: 0.92, 95% CI: 0.86–0.98; p = 0.008) 
were associated with improved survival.
Conclusions: The adoption of BID radiation remains very limited, but 
is more commonly utilized in the academic setting. In this hospital- 
based study, BID fractionation was associated with improved sur-
vival over once-daily fractionation, even at doses ≥60 Gy.
Key Words: Small-cell lung cancer, Hyperfractionated radiation, 
Patterns of care, Chemotherapy.
(J Thorac Oncol. 2015;10: 1770–1775)
Small-cell lung cancer (SCLC) is an aggressive variant of lung cancer that presents with nonmetastatic (limited 
stage) disease in 30% of patients at the time of diagnosis.1 
Current guidelines support the use of concurrent chemoradia-
tion for limited stage SCLC in excess of T1-2N0 and with a 
good performance status.2 Radiation therapy has been shown 
to improve survival for limited stage SCLC,3 although the tim-
ing, dose, and fractionation have been the subject of inves-
tigation. The Intergroup (INT) 0096 trial reported a 5-year 
survival of 26% with 45 Gy in 1.5 Gy per fraction twice-daily 
(BID), establishing this regimen as an accepted standard of 
care.4 However, a patterns of care study analyzing patients 
from 1998 to 1999 reported that as of that point, twice-daily 
fractionation had not gained widespread acceptance.5
The most promising alternative regimen to the BID 
fractionation has been a dose of 70 Gy at 2 Gy/fx once-daily, 
based on three Cancer and Leukemia Group (CALGB) studies 
that reported a pooled 5-year overall survival (OS) of 20%.6 
As a result, the CALGB 30610/Radiation Therapy Oncology 
Group (RTOG) 0538 study is currently randomizing patients 
with limited stage SCLC to either 45 Gy in 1.5 Gy BID or 70 
Gy in 2 Gy once-daily.
In this study, we sought to analyze the National Cancer 
Database (NCDB) to determine the modern patterns of care 
regarding which fractionation schedules are being used. We 
also sought to determine whether any survival differences 
would be noted between the BID and once-daily fractionation.
PATIENTS AND METHODS
The NCDB is a joint project of the American Cancer 
Society and the Commission on Cancer of the American 
College of Surgeons. It is estimated that 70% of all diagnosed 
malignancies in the United States are captured by facilities 
participating in this registry and reported to the NCDB. The 
Commission on Cancer’s NCDB and the hospitals partici-
pating in the NCDB are the source of the de-identiﬁed data 
used in this study. However, they have not veriﬁed and are not 
responsible for the statistical validity or conclusions derived 
by the authors of this study.
Adult patients with nonmetastatic small-cell lung 
cancer who were treated with definitive radiation between 
1999 and 2012 were included. Patients had to have com-
plete information regarding the total radiation dose as 
well as the number of radiation fractions. The NCDB 
does not specifically report whether radiation treatments 
were delivered once or twice daily. However, those who 
received 45 Gy in 30 fractions were classified as having 
undergone accelerated hyperfractionation rather than 1.5 
Gy per day. Patients who received 45 to 72 Gy in 1.8 or 2.0 
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Gy fractions were classified as receiving standard once-
daily treatments. We excluded patients who were identi-
fied as AJCC M1 disease, or patients who were identified 
as having received their radiation treatments to a site other 
than the lung.
Demographic details and chemotherapy use were com-
pared between patients who received BID and once-daily 
treatments via χ2, Fisher’s exact test, and Mann–Whitney test 
where appropriate. Multivariate logistic regression was used 
to determine whether there were any differences in the selec-
tion of BID radiation by age group, race, sex, time interval 
from chemotherapy to radiation therapy initiation, T-stage, 
N-stage, and facility type. Multivariate Cox regression of OS 
was also performed based on age group, race, sex, time inter-
val from chemotherapy to radiation therapy initiation, facil-
ity type, radiation fractionation, and N-staging. The interval 
between the start of chemotherapy and the start of radiation 
was calculated and divided into four quartiles for the purposes 
of this analysis. Survival data were only available from the 
NCDB on patients diagnosed through 2011, due to the short 
follow up available for patients diagnosed in 2012. To ana-
lyze facility type, only patients who were treated at one facil-
ity were included in the multivariate analyses. Kaplan–Meier 
analyses of OS were performed comparing patients who 
received 45 Gy BID with all patients receiving radiation once-
daily together and separately in increasing dose levels (45 Gy 
once-daily, 45–59.4 Gy, 60–61.2 Gy, 62–72 Gy). Signiﬁcant 
values were deﬁned as those with a p value less than 0.05. 
Statistical analysis was performed using SPSS, Version 21 
(IBM Inc, Armonk, NY).
RESULTS
Patient Characteristics
There were 25,045 patients who met the criteria out-
lined above, of which survival data was available for 22,626. 
At a median of 18 months follow up, 77.8% of the patients 
with survival data available were deceased. Most patients 
(89.2%) received multiagent chemotherapy. An additional 
7.7% received either single agent chemotherapy or the 
number of agents was not documented. Chemotherapy was 
started a median of 21 days from the date of diagnosis. 
The most common fractionation scheme was a dose of 46 
to 59.4 Gy in 1.8 to 2 Gy per fraction (44.4%). A dose of 
1.5 Gy delivered BID was utilized in 2821 patients (11.3%). 
Radiation therapy was started a median of 46 days after the 
date of diagnosis. Further details regarding patient charac-
teristics are available in Table 1.
Receipt of BID or Once-Daily Radiation Therapy
Patients who received BID radiation therapy were a 
median age of 63 years, compared with a median age of 66 
years for those receiving once-daily treatments (p < 0.001). 
BID radiation was received in 17.9% of patients who were 
treated at an academic/research facility, compared with 8.1% 
to 9.7% at other facilities (p < 0.001). The median number of 
days until receipt of chemotherapy was 21 days for patients 
receiving BID radiation as well as for those receiving 
once-daily radiation (p = 0.92). Both the median number of 
days until the start of radiation treatments and the duration 
of radiation treatments were shorter in the BID group. The 
median number of days until the start of radiation treatments 
was 38 days in the BID group and 47 days in the once-daily 
group (p < 0.001). The median duration of radiation treat-
ments was 22 days for the BID group and 50 days in the 
once-daily group (p < 0.001).
On multivariate analysis, treatment at an academic cen-
ter was the strongest variable associated with the receipt of 
BID radiation treatment (odds ratio: 2.29, 95% conﬁdence 
interval [CI]: 1.95–2.69; p < 0.001). In addition, treatment at a 
comprehensive community cancer program, earlier initiation 
of radiation, and N-stage ≤2 were more likely to be treated 
with BID radiation. In contrast, increasing age and female sex 
were associated with a lower likelihood of BID fractionation. 
Further details are available in Table 2.
TABLE 1. Patient Characteristics
No (%)
Age (median) 65 years
Sex
  Male 11,295 (45.1%)
  Female 13,750 (54.9%)
Race
  Caucasian 22,729 (90.8%)
  African American 1747 (7.0%)
  Other 569 (2.3%)
Facility type
  Community cancer program 3534 (14.1%)
  Comprehensive community cancer program 15,554 (62.1%)
  Academic/research program 5905 (23.6%)
  Other 52 (0.2%)
Fractionation
  45 Gy/1.5 Gy BID 2821 (11.3%)
  45 Gy/1.8 Gy QD 996 (4.0%)
  46–59.4 Gy/1.8–2 Gy QD 11,116 (44.4%)
  60–61.2 Gy/1.8–2 Gy QD 5095 (20.3%)
  62–72 Gy/1.8–2 Gy QD 5017 (20.0%)
Receipt of chemotherapy
  Yes 24,294 (96.9%)
  No 751 (3.1%)
T-stage
  Tx 4057 (16.2%)
  T0–1 5065 (20.2%)
  T2 7332 (29.3%)
  T3 2847 (11.4%)
  T4 5744 (22.9%)
N-stage
  Nx 3034 (12.1%)
  N0–1 6634 (26.5%)
  N2 11,931 (47.6%)
  N3 3446 (13.8%)
BID, twice-daily; QD, once-daily; Gy, Gray.
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Survival
Treatment with BID radiation was associated with a 
median survival of 22.1 months and a 5-year survival of 23.9%. 
This was superior to the OS in all of the once-daily regimens 
(p < 0.001; Fig. 1). For patients receiving once-daily radiation to 
doses of 45, 46 to 59.4, 60 to 61.2, and 62 to 72 Gy, the median 
survival was 17.2, 18.3, 19.2, and 19.5 months, respectively. The 
corresponding 5-year OS was 16.4%, 17.6%, 17.8%, and 18.1%, 
respectively. On pairwise analysis, survival with BID treatments 
remained signiﬁcantly better than once-daily treatments for all 
each dose level (p < 0.001 for all comparisons to BID).
Multivariate Analysis
On multivariate analysis, treatment with BID radiation 
was associated with improved OS (hazard ratio [HR]: 0.92, 
95% CI: 0.86–0.98; p = 0.008) relative to once-daily radiation 
to a dose of 62 to 72 Gy. Correspondingly, treatment with once-
daily radiation to a dose of 45 Gy or 46 to 59.4 Gy were asso-
ciated with inferior survival (HR: 1.14, 95% CI: 1.04–1.25; 
p = 0.004 and HR: 1.07, 95% CI: 1.02–1.12; p = 0.007, respec-
tively). Early initiation of radiation relative to chemotherapy 
was also associated with improved survival, with a HR of 0.87, 
95% CI: 0.83–0.92; p value less than 0.001 for initiation of 
radiation within 21 to 47 days after chemotherapy, and a HR 
of 0.89, 95% CI: 0.85–0.93, p value less than 0.001 for initia-
tion of radiation within 0 to 21 days of the start of chemother-
apy. Female sex (HR: 0.80, 95% CI: 0.77–0.82; p < 0.001) as 
well as treatment at an academic program (HR: 0.88, 95% CI: 
0.83–0.93; p < 0.001) or a comprehensive community cancer 
program (HR: 0.91, 95% CI: 0.87–0.96; p < 0.001) were also 
associated with improved survival. Further details are avail-
able in Table 3.
DISCUSSION
Our study demonstrates that there is considerable vari-
ability in the radiation dose and fractionation used for the 
management of limited stage SCLC. The INT-0096 trial estab-
lished BID radiation with concurrent chemotherapy as the 
preferred regimen for the treatment of limited stage SCLC.4 
An analysis of practice patterns in the United States found 
that only 10% of SCLC patients received BID radiation before 
publication of the INT-0096 results in 1999.5 Our study of 
patients diagnosed from 1999 to 2012 indicates that utiliza-
tion of BID radiation has risen only slightly to 11.3% during 
TABLE 2. Multivariate Logistic Regression for Treatment 
with Twice-Daily Radiation
Odds Ratio  
(95% CI) p
Age grouping
  ≤60 1
  61–70 0.85 (0.77–0.94) 0.001
  >70 0.60 (0.53–0.68) <0.001
Race
  Caucasian 1
  African American 0.85 (0.71–1.02) 0.07
  Other 1.14 (0.86–1.52) 0.37
Sex
  Male 1
  Female 0.88 (0.81–0.97) 0.007
Facility typea
  Community cancer program 1
  Comprehensive community cancer 
program
1.24 (1.06–1.44) 0.007
  Academic/research program 2.29 (1.95–2.69) <0.001
T-stage
  Tx 1
  T0–1 0.98 (0.81–1.18) 0.83
  T2 0.91 (0.76–1.08) 0.28
  T3 0.90 (0.74–1.11) 0.33
  T4 0.86 (0.72–1.03) 0.10
N-stage
  Nx 1
  N0–1 1.26 (1.02–1.56) 0.03
  N2 1.35 (1.11–1.64) 0.003
  N3 1.09 (0.88–1.36) 0.44
Initiation of chemotherapy
  First quartile (≥48 days before RT) 1
  Second quartile (21–47 days before RT) 2.08 (1.80–2.40) <0.001
  Third quartile (0–20 days before RT) 2.12 (1.85–2.42) <0.001
  Fourth quartile (1 or more days after RT) 1.75 (1.44–2.11) <0.001
aFacility type limited to patients who received their treatments at one facility. There 
were no patients who received twice-daily radiation in “Other” facilities.
RT, radiation therapy.
fIGURE 1. Kaplan–Meier curve for overall survival accord-
ing to fractionation schedule, p < 0.001. BID, twice-daily 
radiation; QD, once-daily radiation, radiation dose is given in 
centiGray.
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this time period. Underutilization was especially prominent 
at community centers, where only 8.1% to 9.7% of patients 
received BID radiation, compared with 17.9% of patients 
treated at an academic/research facility.
There are several potential reasons that BID radia-
tion has yet to be widely adopted. One possibility is that it 
may be related to the increased risk of severe acute toxicity, 
particularly esophagitis, associated with this regimen. The 
INT-0096 trial reported a twofold increase in the rate of the 
severe (grade 3–4) esophagitis (32% with BID versus 16% 
with once-daily), whereas rates of severe esophagitis in phase 
I/II trials of dose-escalated once-daily radiation have ranged 
from 21% to 23%.6,7 However, modern radiation techniques, 
as well as the omission of elective nodal irradiation may lead 
to reduced toxicity. A recent report by Grant et al.8 found 
that when they treated patients to a dose of 45 Gy BID via 
three-dimensional conformal radiotherapy, the grade 3 esoph-
agitis was 26%. Subsequently, they modiﬁed their practice 
to incorporate intensity-modulated radiation therapy along 
with four-dimensional computed tomography-based planning 
and elimination of elective nodal irradiation, and found that 
the rate of grade 3 esophagitis was reduced to 11.5%. While 
modern radiation techniques may reduce the barrier associ-
ated with patient toxicity, an additional obstacle may in fact 
be the inconvenience of this regimen. Twice-daily irradiation 
typically entails a minimum of 6 hours in between treatments, 
requiring the patient to either remain at the clinic for an entire 
day or travel back and forth multiple times. The precise role of 
patient inconvenience on the decision making process for BID 
versus once-daily radiation is beyond the scope of this study 
but warrants further investigation.
A third potential reason for the lack of adoption of BID 
treatments may be related to the critiques associated with the 
INT-0096 trial, namely the low biologic effective dose of its 
once-daily radiation arm.9 Many argue that the study does not 
necessarily demonstrate the superiority of BID over once-
daily radiation but rather the superiority of a higher biologic 
effective dose. In fact, data from phase I/II trials have sug-
gested a dose–response relationship and that dose-escalated 
once-daily radiation can result in comparable survival to BID 
radiation.6 While these aforementioned factors cannot be 
directly addressed via the NCDB, it seems likely that some 
combination of these three issues have led to the very low uti-
lization rate of BID radiation that we observed in this study.
Interestingly, the survival results in our study mirror the 
ﬁndings reported by the INT-0096 trial. For patients receiving 
BID radiation, we report a median survival of 22.1 months 
and 5-year OS of 23.9%, compared with a median survival of 
23 months and 5-year OS of 26% in the INT-0096 trial. We did 
detect a survival beneﬁt to escalating the radiation dose ≥60 
Gy for patients treated with once-daily radiation, with 5-year 
OS improving from 16.4% for 45 Gy to 17.8%–18.1% for ≥60 
Gy. However, BID radiation still had better survival compared 
with patients receiving ≥60 Gy once-daily (23.9% versus 
17.8%–18.1%; p < 0.001). For patients receiving once-daily 
radiation, median survival ranged from 17.2 to 19.5 months 
with 5-year OS ranging from 16.4% to 18.1%. These estimates 
are slightly lower than those reported by several other studies, 
including a pooled analysis of the CALGB trials (median sur-
vival of 19.9 months with 5-year OS of 20%). In addition, a 
retrospective series from the Dana-Farber Cancer Institute and 
Brigham and Women’s Hospital reported a median survival of 
22.8 months with 5-year OS of 30% in patients treated with 
dose-escalated once-daily radiation (median dose 61.2 Gy 
with range 50–66.6 Gy).10 An accelerated hypofractionated 
schedule (42 Gy in 2.8 Gy fractions) has also been proposed, 
with a retrospective series demonstrating median survival of 
24 months with 3-year OS of 39.4%.11
Ultimately, prospective randomized data are needed to 
address this issue. A phase III trial jointly run by the CALGB/
Radiation Therapy Oncology Group (CALGB 30610/RTOG 
0538) is ongoing. This trial randomizes participants to either 
45 Gy in 1.5 Gy fractions BID or 70 Gy in 2 Gy fractions 
once-daily. A third treatment arm consisting of 61.2 Gy in 1.8 
TABLE 3. Multivariate Analysis for Overall Survival
Hazard Ratio 
(95% CI) p
Age grouping
  ≤60 1
  61–70 1.16 (1.11–1.21) <0.001
  >70 1.46 (1.39–1.52) <0.001
Race
  Caucasian 1
  African American 0.99 (0.93–1.06) 0.83
  Other 0.96 (0.85–1.08) 0.49
Sex
  Male 1
  Female 0.80 (0.77–0.82) <0.001
Facility typea
  Community cancer program 1
  Comprehensive community cancer Program 0.91 (0.87–0.96) <0.001
  Academic/research program 0.88 (0.83–0.93) <0.001
  Other 0.56 (0.25–1.24) 0.15
  Fractionation
  45 Gy/1.5 Gy BID 0.92 (0.86–0.98) 0.008
  45 Gy/1.8 Gy QD 1.14 (1.04–1.25) 0.004
  46–59.4 Gy/1.8–2 Gy QD 1.07 (1.02–1.12) 0.007
  60–61.2 Gy/1.8–2 Gy QD 1.04 (0.98–1.10) 0.18
  62–72 Gy/1.8–2 Gy QD 1
N-stage
  Nx 1
  N0–1 0.76 (0.72–0.80) <0.001
  N2 1.01 (0.96–1.07) 0.64
  N3 1.15 (1.08–1.23) <0.001
Initiation of chemotherapy
  First quartile (≥48 days before RT) 1
  Second quartile (21–47 days before RT) 0.87 (0.83–0.92) <0.001
  Third quartile (0–20 days before RT) 0.89 (0.85–0.93) <0.001
  Fourth quartile (1 or more days after RT) 0.99 (0.93–1.06) 0.75
aFacility type limited to patients who received their treatments at one facility. There 
were no patients who received twice-daily radiation in “Other” facilities.
BID, twice-daily; QD, once-daily, Gy, Gray; RT, radiation therapy.
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Gy fractions with concomitant BID boost for nine fractions 
was recently closed in 2013. A similar phase III trial is being 
run by the European Organization for Research and Treatment 
of Cancer. This trial randomized patients to either 45 Gy in 
1.5 Gy fractions BID or 66 Gy in 2 Gy fractions once-daily. 
Accrual of this trial completed in 2014 and results have yet to 
be reported.
Several factors may account for the survival beneﬁt 
observed with BID radiation. The accelerated repopulation 
of tumor cells is a potential cause of treatment failure after 
both chemotherapy and radiation therapy,12 and thus the 
time between the start of any treatment to the end of radia-
tion therapy has been established as an important predictor 
of OS.13 Our study found a much shorter duration of radia-
tion therapy with BID radiation in comparison to once-daily 
radiation (median 22 days versus 50 days; p < 0.001), which 
suggests BID radiation may help to diminish the detrimental 
effect of accelerated repopulation by shortening overall treat-
ment time. Moreover, we found that patients receiving BID 
radiation started their radiation therapy signiﬁcantly earlier 
than those receiving once-daily radiation (median time to start 
of radiation 38 days versus 47 days; p < 0.001) despite simi-
lar chemotherapy initiation times (both groups with a median 
of 21 days). The optimal timing of radiation therapy relative 
to chemotherapy is controversial as several randomized tri-
als have reported contradictory results.14–17 However, system-
atic reviews suggest early radiation therapy (within 9 weeks 
of initiation of therapy or before cycle 3 of chemotherapy) 
may improve survival.18,19 In this study, we found that patients 
treated with radiation therapy within the middle two quartiles 
(between 0 and 47 days from the initiation of chemotherapy) 
had improved survival on multivariate analysis relative to later 
initiation of radiation therapy.
The impact of sex on survival in patients with SCLC 
has been previously investigated. In a single institution retro-
spective review, Videtic et al. reported that women had greater 
5-year OS than men (12.5% versus 2.5%; p = 0.07). This asso-
ciation was signiﬁcant independent of other treatment vari-
ables, including smoking cessation and radiation treatment 
interruptions, suggesting that the mechanism for improved 
survival in women involves inherent differences in biology 
rather than behavioral differences. Our ﬁndings conﬁrmed 
that female sex was strongly associated with improved OS 
(HR: 0.8, 95% CI: 0.77–0.82). Given the inherent biases of a 
population-based database, these ﬁndings are hypothesis gen-
erating. However, further studies should consider the potential 
impact of sex in limited-stage SCLC.
The ﬁnding of improved survival in those patients being 
treated at an academic or comprehensive community cancer 
center is one that warrants further study. It is difﬁcult to deter-
mine if selection bias may have played a role in improved 
outcomes in these centers based on our analysis. However, it 
is also a possibility that care in an academic or comprehen-
sive center may be of higher quality. This may be manifested 
through improved staging, better adherence to treatment 
guidelines and treatment schedules, improved quality of radi-
ation delivery, and improved support during extremely toxic 
treatment.
The major strength of this study is the large number of 
patients included, with >25,000 patients. However, there are 
several important limitations of this study. The NCDB does 
not encode performance status so potential differences in per-
formance status between those receiving BID versus once-
daily radiation could not be examined. It is possible that more 
patients with poor performance status received once-daily 
radiation due to better tolerability and this could potentially 
account for the differences in survival that we observed. In 
addition, it is unclear whether unmeasured selection bias also 
played a role in patients who received BID radiation starting 
their treatments sooner than those receiving once-daily radia-
tion, which may have beneﬁcially impacted their survival. 
Another limitation to our study is that we were only able to 
assess OS but not disease-speciﬁc survival. Presumably, most 
patients with SCLC are dying of their disease but we could 
not examine other-cause mortality in our study. As toxicity 
data are not available in the NCDB, we could not conﬁrm 
the increased risk of severe acute toxicity with BID radiation 
observed in previous studies. Finally, the NCDB does not sep-
arately encode information on the use of prophylactic cranial 
irradiation (PCI). The use of PCI has been shown to increase 
3-year OS by 5.4% for patients with limited stage SCLC.20 It 
is possible that PCI was more heavily used in academic and 
comprehensive cancer centers, which may have also contrib-
uted to the survival differences in this study.
In conclusion, we found that BID radiation was more 
likely to be delivered at an academic facility but neverthe-
less, only 11.6% of patients with limited stage SCLC receive 
BID radiation. However, those who received 45Gy BID were 
found to have the best 5-year OS compared with once-daily 
fractionation even when compared with escalated doses above 
61.2 Gy. This hypothesis-generating study supports the use of 
twice daily radiation where feasible while we await the results 
from randomized trials.
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